300639.SHE Guangdong Hybribio Biotech Co Ltd
- Market cap
- CNY 3.59B
- P/E
- 55.6x
- P/B
- 1.01x
- ROE
- 2.5%
- Dividend yield
- 0.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300639.SHE undervalued?
Graham number300639.SHE trades 57.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Hybribio Biotech Co Ltd fundamental analysis
No fundamental analysis for Guangdong Hybribio Biotech Co Ltd yet.
Guangdong Hybribio Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. The company offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical P…
Full company profileGuangdong Hybribio Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Hybribio Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 398M | 479M | 580M | 729M | 1.35B | 2.67B | 5.60B | 1.10B | 816M | 670M | 611M |
| Gross Profit | 341M | 400M | 485M | 587M | 993M | 1.81B | 3.79B | 662M | 375M | 304M | 287M |
| Operating Income | 80.4M | 110M | 126M | 156M | 469M | 1.07B | 2.19B | 42.6M | -822M | -136M | -58.1M |
| EBITDA | 110M | 137M | 157M | 196M | 515M | 1.15B | 2.31B | 208M | -673M | -6.71M | 119M |
| Net Income | 76.1M | 93.2M | 114M | 147M | 363M | 852M | 1.73B | 140M | -655M | -131M | 93.2M |
| EPS | 0.17 | 0.17 | 0.19 | 0.25 | 0.59 | 1.29 | 2.62 | 0.25 | -1.02 | -0.20 | 0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 579M | 1.07B | 1.19B | 1.30B | 2.86B | 4.23B | 6.73B | 5.73B | 4.62B | 4.15B | 4.17B |
| Total Liabilities | 77.5M | 98.7M | 108M | 112M | 323M | 756M | 1.50B | 627M | 576M | 486M | 566M |
| Shareholders' Equity | 489M | 961M | 967M | 1.08B | 2.39B | 3.19B | 4.91B | 4.86B | 4.11B | 3.75B | 3.68B |
| Cash & Short-term Investments | 51.4M | 186M | 62.8M | 262M | 1.25B | 1.20B | 1.41B | 1.07B | 963M | 799M | 756M |
| Total Debt | 10.0M | 23.5M | 140K | 232K | 75.3M | 185M | 139M | 47.8M | 79.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 63.6M | 79.2M | 80.4M | 113M | 311M | 631M | 1.31B | 320M | 78.8M | 342M | - |
| Capital Expenditure | 77.3M | 67.0M | 144M | 197M | 287M | 641M | 734M | 385M | 148M | 92.4M | 137M |
| Free Cash Flow | -13.7M | 12.2M | -64.0M | -83.7M | 24.2M | -9.73M | 575M | -65.7M | -69.6M | 249M | 65.2M |
| Ratios | |||||||||||
| ROE | 15.5% | 9.7% | 11.8% | 13.6% | 15.2% | 26.7% | 35.2% | 2.9% | -15.9% | -3.5% | 2.5% |
| ROA | 13.1% | 8.7% | 9.6% | 11.4% | 12.7% | 20.1% | 25.6% | 2.5% | -14.2% | -3.2% | 2.2% |
| Net Profit Margin | 19.1% | 19.5% | 19.7% | 20.2% | 26.8% | 31.9% | 30.8% | 12.7% | -80.3% | -19.6% | 15.3% |
| Debt to Equity | 0.02x | 0.02x | 0.00x | 0.00x | 0.03x | 0.06x | 0.03x | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong Hybribio Biotech Co Ltd dividends
- Dividend yield
- 0.10%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 23, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 3.50M | 0.01 | - |
| 2024 | CNY 44.5M | 0.07 | - |
| 2023 | CNY 151M | 0.27 | 107.4% |
| 2022 | CNY 102M | 0.15 | 5.9% |
| 2021 | CNY 69.8M | 0.11 | 8.2% |
| 2020 | CNY 42.5M | 0.07 | 11.7% |
| 2019 | CNY 44.3M | 0.07 | 30.0% |
| 2018 | CNY 45.5M | 0.08 | 39.9% |
| 2017 | CNY 19.3K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 22, 2023.
Who owns Guangdong Hybribio Biotech Co Ltd
- Insiders 46.04%
- Institutions 0.98%
- Public & others 52.98%
- Shares outstanding 647M
- Free float 367M
Guangdong Hybribio Biotech Co Ltd company profile
- Company name
- Guangdong Hybribio Biotech Co Ltd
- Ticker
- 300639.SHE
- ISIN
- CNE100002N51
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,990
- Fiscal year end
- December
- Address
- D5-3-3-4, North High-tech Zone, Chaozhou, China, 521000
- Phone
- 86 76 8285 2923
- Website
- hybribio.cn
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. The company offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. It operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is headquartered in Chaozhou, China.
Guangdong Hybribio Biotech Co Ltd management
7- Ms. Jianyu WangGM & Director · born 1961
- Mr. Qinghui LiFinancial Director · born 1965
- Mr. Zhisheng GuanExecutive Deputy GM & Non Independent Director · born 1984
- Mr. Xiaochuan LiChief Medical Officer · born 1964
- Mr. Yi ChenDeputy GM & Board Secretary · born 1979
- Ms. Danrong WengDeputy General Manager · born 1981
- Cuihong LuoAccounting Supervisor